0606eurM

Everyone knows Magnificent 7 stocks, but are GRANOLAS the new one in 2025?

Macro

Note: This article was translated into English using Copilot.

Most investors know, or have already invested in, one of the Magnificent 7 stocks (Mag7). The Mag7 covers seven US tech stocks, and is a collective term for Apple, NVIDIA, Tesla, Alphabet, Amazon, Meta and Microsoft, which in the last few years have driven a large part of the US and global stock returns.

In Europe, they have their own "darlings" called, GRANOLAS. GRANOLAS is probably a term that is less well known among investors in Asia, but when you hear the names that the group covers, most people know many of the companies. Instead of 7 shares in Mag7, GRANOLAS consists of 10 of the largest European companies; GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP and Sanofi.

While the Mag7 stocks are all technology stocks, GRANOLAS is very heavy in pharmaceutical stocks, but is more diversified and also includes technology stocks such as ASML and SAP as well as consumer stocks such as Nestle, L'Oreal and LVMH.

The return on large European stocks has significantly underperformed US technology stocks. As can be seen in the graph below, the Nasdaq100 index, where the Mag7 shares constitute significantly, is up by a whopping 131% since the start of 2020, while the Euro Stoxx 600, where GRANOLAS make up a lot of the index, is only up by 22% in the same period.

However, this does not mean that you should judge the European giants just yet, because right now may be a good time to take an extra look at the GRANOLAS shares.

oskb-eu-vs-us

Source: Bloomberg, Saxo

Looking at Mag7 and GRANOLAS shares across valuation, earnings growth and momentum in companies' earnings growth relative to 2024 could indicate that GRANOLAS shares should once again have a place in a balanced investment portfolio.

The figures in the tables below are based on analysts' average expectations for 2025.

It is of course not certain that the companies will reach the expectations that are placed on them, but this gives a clear indication of what the market expects the various companies to deliver in terms of profits in 2025, and how they will be valued in relation to the expected 2025 results.

As shown in the table below, Mag7 shares are trading at an average of 44.5x their expected earnings in 2025. It is especially Tesla's valuation that pulls up the average, with the remaining Mag7 shares valued at around 25-35x their expected 2025 earnings.

Looking at the average GAAP EPS growth for the Mag7 companies, the market expects EPS (earnings per share) to grow by an average of 24.2% in 2025. GAAP stands for "Generally Accepted Accounting Principles", and in short, means that earnings growth is calculated based on the companies' actual financial figures, and not their adjusted financial figures.

While 24.2% earnings per share growth sounds attractive, as an investor, it's worth noting that the expected earnings growth is 15.2 percentage points lower than it was in 2024. In other words, earnings growth is still strong in Mag7, but the momentum in the shares' earnings growth is negative among all companies in the group except Tesla and Apple, which are expected to deliver higher earnings growth in 2025 compared to 2024.

Mag7 v2Source: Saxo


From the same numbers, GRANOLAS shares look attractive compared to Mag7 shares. On the valuation, GRANOLAS trades at an average multiple of 21.3x its expected 2025 earnings, which is about half of the Mag7 shares' valuation.

The expected earnings growth per share is on average 30.2% for 2025, which is higher than the growth expected in Mag7 earnings. Earnings growth momentum is also positive for GRANOLAS shares, with 24.4 percentage points higher earnings per share growth expected in 2025 compared to 2024.

In short, GRANOLAS wins over the Mag7 shares on both valuation, expected earnings growth and expected momentum in earnings growth, which suggests that investors should give Europe's GRANOLAS shares an extra look instead of only focusing on the Mag7 shares to find growth and quality stocks for the investment portfolio.

Granolas v2Source: Saxo

Disclaimer

Confidentiality and Usage:
You may not reproduce, distribute, or transmit this material or any portion thereof without prior written permission from Saxo.

Nature of Information:
The information provided herein is based on current market conditions and analysts' opinions, which may reflect personal views of the author, and are subject to change without notice. This material does not include a record of any trading prices, or an offer of, or solicitation for, or endorsement to enter into any transaction in any investment product. Any forecast on the economy, markets and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the investment product subject of this material.

Responsibility and Liability:
Saxo accepts no liability for any use that may be made of these comments or for any consequences that arise from such use. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The information provided in this material is solely for information only. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning specific situations of any person. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase an investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether any investment product mentioned in this publication is suitable for you.

Notwithstanding the above, insofar as any information provided herein contains research analyses or reports concerning any investment product authored by any foreign research house and is issued or promulgated to a person in Singapore who is not an accredited investor, expert investor, and/or institutional investor, Saxo Capital Market Pte. Ltd. accepts legal responsibility for the contents of this material to the extent required by law. Recipients of such material are to contact Saxo Capital Markets Pte. Ltd. in respect of any matters arising from, or in connection with, this material.

Risk Disclosure:
Trading in investment products involve significant risk, including the risk of losing your entire investment. Historical returns are not a guarantee of future returns. Prices can both rise and fall, and there is a risk that you will not get back the money you invested.

Conflicts of interest:
The author may hold positions in the investment products mentioned. The author does not own positions in the underlying investment product exceeding 0.5% of its market capitalisation, save as otherwise declared. The author is not permitted to trade the mentioned investment products within the first 24 hours after the publication of this article.

Saxo maintains partnerships with companies that compensate Saxo for promotional activities conducted on its platform. Additionally, Saxo has agreements with certain partners who provide retrocession contingent upon clients purchasing specific investment products offered by these partners. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Publication details:
If any listed companies are the subject of the material, the content has not been submitted to the companies in question prior to publication.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Saxo is part of the J. Safra Sarasin Group.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.